Yang Xie, Ph.D

Speaker Yang Xie, PhD Associate Professor UT Southwestern Medical Center Time: May 30, 2013  (Thursday) 11:00 – 12:00 Location: FIT Building 1-312, Tsinghua University ABSTRACT: Randomized clinical trials have demonstrated the survival benefit of adjuvant chemotherapy (ACT) in resected non-small-cell lung cancer (NSCLC). Because the response to standard chemotherapy in lung cancer varies, it would be helpful to prospectively identify patients who will benefit from ACT to guide the treatment plan. In this talk, I will present several studies aiming to identify clinically useful gene expression markers for prognosis and response to adjuvant chemotherapy in lung cancer patients. In the first study, we developed a novel Bioinformatics approach to identify a robust prognosis signature for NSCLC based on genome-wide expression profiling of clinically available formalin-fixed and paraffin-embedded (FFPE) samples. In the second study, we used a systems biology approach to identify an 18-hub-gene signature that can robustly predict the prognosis of patients with early stage adenocarcinoma of the lung. Furthermore, we integrated these hub genes with genetic aberration and genome-wide RNAi functional data to derive a 12-gene set that is predictive for survival benefit with ACT these datasets. Finally, I will briefly describe our strategy to predict synergistic effects of drug combinations using genomics data, which won the best performance method in the NCI-DREAM challenge.